



IFW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Chang, Xiao-Jia

Serial No: 10/615,343

Filed: July 8, 2003

For: *Methods of Producing Antibodies for  
Diagnostics and Therapeutics*

Examiner: Grun, James Leslie


Art Unit: 1641

Confirmation No.: 8723

Attorney Docket No. IGA-003.01

**CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)**

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail, postage prepaid, in an envelop addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on May 3, 2005

  
\_\_\_\_\_  
Todd Williams

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT**  
**UNDER 37 C.F.R. §1.97(b)**

Submitted herewith on Form PTO-1449 is a listing of documents known to Applicants and/or their attorney in compliance with the requirements of 37 C.F.R. § § 1.56 and 1.97(b)(3).

Copies of References BD through BI are enclosed.

Applicants respectfully request that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached form.

This submission does not represent that a search has been made or that no better art exists. Nor does it constitute an admission that each of the listed documents is material or constitutes "prior art." If the Examiner applies any of the listed documents as prior art against any claim in the application and Applicants determine that the cited documents do not constitute

"prior art" under United States law, Applicants reserve the right to present to the Office the relevant facts and law regarding the appropriate status of such documents.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more documents be applied against the claims of the present application.

Under 37 C.F.R. § 1.97(b)(3), this Information Disclosure Statement is being filed before the mailing date of the first Office Action on the merits; therefore, no fee is believed to be due in connection with the filing of this disclosure. If, however, a first Office Action on the merits issues in this application bearing a mailing date prior to the date of this Information Disclosure Statement, please charge the appropriate fees as required under 37 C.F.R. § 1.17(p) to our **Deposit Account No. 06-1448; Ref. No. IGA-003.01.**

Respectfully Submitted,

**Customer No: 25181**

Patent Group

Foley Hoag LLP

155 Seaport Boulevard

Boston, MA 02210-2600

Tel. (617) 832-1000

Fax. (617) 832-7000

Date: May 3, 2005

By: 

Isabelle Clauss

Reg. No. 47,326

Attorney for Applicants

Form PTO-1449

**INFORMATION DISCLOSURE CITATION  
IN AN APPLICATION**  
*(Use several sheets if necessary)*

MAY 05 2005

Docket Number (Optional)

GIA-003.01

Application Number

10/615,343

Applicant  
Chang, Ziao-JiaFiling Date  
July 8, 2003Group Art Unit  
1641**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA 5,401,635	03/28/1995	Nakamura et al			
	AB 5,463,026	10/31/1995	Nakamura et al			
	AC 5,552,526	09/03/1996	Nakamura et al			
	AD 5,599,707	02/04/1997	Nakamura et al			
	AE 5,631,351	05/20/1997	Nakamura et al			
	AF 5,652,092	07/29/1997	Vitek et al			
	AG 5,693,478	12/02/1997	Vitek et al			
	AH 5,807,752	09/15/1998	Brizgys et al			
	AI 5,747,650	05/05/1998	Kulesz-Martin			
	AJ 5,705,341	01/06/1998	Nakamura et al			
	AK 5,916,561	06/29/1999	Adolf et al			
	AL 6,010,865	01/04/2000	Ponta et al			
	AM 6,252,050 B1	06/26/2001	Ashkenazi et al			
	AN 6,372,441	04/16/2002	Heider et al			
	AO US2002/0061571	05/23/2002	Mahadevan et al			
	AP 6,421,613	07/16/2002	Nadimpalli et al			
	AQ 6,451,309 B2	09/17/2002	Hooper et al.			
	AR US2002/0194632	12/19/2002	McConlogue et al			
	AS US2003/0022353	01/30/2003	Litwack et al			
	AT US2003/0032073	02/13/2003	Heider et al			
	AU US2003/0093819	05/15/2003	D'Andrea et al			
	AV US2003/0157599	08/21/2003	Gudmundsson			
	AW US2003/0165958	09/04/2003	Hardy et al			
	AX US2003/0190702	10/09/2003	Maihle et al			
	AY US2003/0224393	12/04/2003	Gudmundsson			
	AZ 6,703,020	03/09/2004	Thorpe et al			
	BA US2004/0214238	10/28/2004	Lipscombe et al			
	BB US2004/0120949	06/24/2004	Guenther et al			

Form PTO-1449

**INFORMATION DISCLOSURE CITATION****IN AN APPLICATION***(Use several sheets if necessary)*

Docket Number (Optional)

GIA-003.01

Application Number

10/615,343

Applicant  
Chang, Ziao-JiaFiling Date  
July 8, 2003Group Art Unit  
1641

BC

US2004/0259114

12/23/2004

Riegel et al

**FOREIGN PATENT DOCUMENTS**

DOCUMENT NUMBER

DATE

COUNTRY

CLASS

SUBCLASS

Translation

YES

NO

**OTHER DOCUMENTS***(Including Author, Title, Date, Pertinent Pages Etc.)*

BD

Ran, Y. et al., Construction of Anti-Human VEGF165 Chimeric Antibodies and Expression in Eukaryotic Cells, Zhonghua Zhong Liu Za Zhi 1999 Nov; 21(6):412-5. (Abstract Only)

BE

Schlaeppli, JM et al., Characterization Of A New Potent, In Vivo Neutralizing Monoclonal Antibody To Human Vascular Endothelial Growth Factor, J Cancer Res Clin Oncol 1999;125(6):336-42. (Abstract Only)

BF

Chen, JH et al., Monoclonal Antibodies Against Vascular Endothelial Growth Factor 165 (VEGF165: Neutralization Of Biological Activity And Recognition Of The Epitope, Biochem Mol Biol Int 1999 Feb;47(2):161-9. (Abstract Only)

BG

Kim, KJ et al., The Vascular Endothelial Growth Factor Proteins: Identification Of Biologically Relevant Regions By Neutralizing Monoclonal Antibodies, Growth Factors 1992;7(1):53-64. (Abstract Only)

BH

Becker, I et al., Novel Mutation-specific Monoclonal E-cadherin Antibodies Make Possible Allele Differentiation At The Protein Level In Tumors, Verh Dtsch Ges Pathol 1999; 83:233-9. (Abstract Only)

BI

Becker, K et al., Analysis Of E-cadherin In Diffuse-Type Gastric Cancer Using A Mutation-Specific Monoclonal Antibody, Am. J. Pathology, 1999;155:1803-1809.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.